OnCo
trialsTrial

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

A phase 2 trial of Poziotinib in Breast cancer, run by Spectrum Pharmaceuticals, Inc, recorded as terminated on the registry.